# Niclosamide Formulations for the Treatment of Influenza Infections

> **NIH NIH R43** · MOLECULAR EXPRESS, INC. · 2022 · $298,479

## Abstract

Project Summary
 The principal goal of this project is to demonstrate that the FDA-approved anthelminthic drug,
niclosamide, can be reformulated in a synthetic lung surfactant which can be aerosolized for the treatment of
infections caused by respiratory viruses. The studies proposed in this SBIR Phase I application will be focused
on testing this concept by suspending niclosamide loaded liposomes in our proprietary lung surfactant
technology (Niclosurf) and testing candidate Niclosurf formulations in a mouse influenza challenge model. The
effectiveness of Niclosurf as a treatment for respiratory viral infections caused by influenza will be evaluated.

## Key facts

- **NIH application ID:** 10385194
- **Project number:** 1R43AI167394-01
- **Recipient organization:** MOLECULAR EXPRESS, INC.
- **Principal Investigator:** Gary Fujii
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $298,479
- **Award type:** 1
- **Project period:** 2022-07-08 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10385194

## Citation

> US National Institutes of Health, RePORTER application 10385194, Niclosamide Formulations for the Treatment of Influenza Infections (1R43AI167394-01). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10385194. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*